These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29303009)

  • 1. Dyslipidaemia in the elderly: to treat or not to treat?
    Katsiki N; Kolovou G; Perez-Martinez P; Mikhailidis DP
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):259-278. PubMed ID: 29303009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark.
    Graversen L; Christensen B; Borch-Johnsen K; Lauritzen T; Sandbaek A
    Scand J Prim Health Care; 2010 Mar; 28(1):47-54. PubMed ID: 19929180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go.
    Firmann M; Marques-Vidal P; Paccaud F; Mooser V; Rodondi N; Waeber G; Vollenweider P
    Eur J Cardiovasc Prev Rehabil; 2010 Dec; 17(6):682-7. PubMed ID: 20700055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of dyslipidaemia - evidence and practical recommendations.
    Nestel PJ; O'Brien R; Nelson M
    Aust Fam Physician; 2008 Jul; 37(7):521-7. PubMed ID: 18592069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering therapy in patients 75 years and older: clinical priority or superfluous therapy?
    Phan BA; Bittner V
    Prog Cardiovasc Dis; 2014; 57(2):187-96. PubMed ID: 25216618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database.
    Asghari S; Aref-Eshghi E; Godwin M; Duke P; Williamson T; Mahdavian M
    BMJ Open; 2015 Dec; 5(12):e007954. PubMed ID: 26656980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of dyslipidaemia in childhood.
    Kusters DM; Vissers MN; Wiegman A; Kastelein JJ; Hutten BA
    Expert Opin Pharmacother; 2010 Apr; 11(5):739-53. PubMed ID: 20210683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease prevention strategies for type 2 diabetes mellitus.
    Katsiki N; Purrello F; Tsioufis C; Mikhailidis DP
    Expert Opin Pharmacother; 2017 Aug; 18(12):1243-1260. PubMed ID: 28685623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on management of paediatric dyslipidaemia.
    Bansal N; Kumar S; Brar PC
    Curr Opin Endocrinol Diabetes Obes; 2023 Feb; 30(1):52-64. PubMed ID: 36541082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.
    Pirro M; Del Giorno R; Lupattelli G; Mannarino MR; Roscini AR; Covelli D; Schillaci G; Pasqualini L; Bagaglia F; Siepi D; Mannarino E
    Eur J Intern Med; 2011 Aug; 22(4):412-7. PubMed ID: 21767761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies in dyslipidaemia management.
    Stock J
    Atherosclerosis; 2012 Apr; 221(2):321-4. PubMed ID: 22305261
    [No Abstract]   [Full Text] [Related]  

  • 18. More clinical lessons from the FIELD study.
    Fazio S
    Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.